CancerSeq™ AMS Paraffin Tissue Curl

T2235152-AC-C201033 C201033
  • Species: Human
  • Disease: Carcinoma
  • Applications: NGS, IHC, RNAScope
$499.00
Need help with your order?
Find out more about placing an order here or contact us for technical support.
Pricing is for US customers only. For international pricing, please contact your local distributor. View Distributors Here.

Product Description

BioChain’s CancerSeq AMS formalin-fixed paraffin-embedded (FFPE) tissues are non-small-cell lung carcinoma (NSCLC) tumor tissues that have been prescreened extensively for single nucleotide polymorphisms (SNPs) and insertions & deletions (indels). Targeted Next Generation Sequencing (NGS), using Thermo Fisher’s Ion AmpliSeq panel, was performed to identify mutations and mutational hotspots in 35 well-characterized genes that are associated with oncology. These tissues are ideal for verification, genotyping, or identification of new mutational hotspots.
Looking for multiple donors or additional samples?

Product Specifications

Features Specifications
Size 5 Curls
Tissue Name Lung
Shipping Ambient Temperature
Species Human
Sex Female
Age At Sampling 49 yrs
Tissue Lung
Diagnosis Central Adenocarcinoma
Donor Status Tumor
Gene Characterization NGS
Product Type Tissue
Disease Carcinoma
Applications NGS, IHC, RNAScope
Clinical Diagnosis Adenocarcinoma
Donor Information Female: 49 yrs old, 1 donor

Targeted Next Generation Sequencing (NGS), using Thermo Fisher’s Ion AmpliSeq panel, was performed to identify mutations and mutational hotspots in 35 well-characterized genes that are associated with oncology. These tissues are ideal for verification, genotyping, or identification of new mutational hotspots. Tissues found to not contain any mutational hotspots in a gene of interest may also be considered to be used as a negative control for assay performance.

The advantage of using BioChain’s CancerSeq AMS real tumor tissue versus genetically engineered tumor cell lines is that the tissues are far more representative of real clinical disease. Cancer cell lines or genetically altered cell lines have been used widely for in vitro tumor models, but these possess only a small proportion of the genetic variances seen in tumor tissues. Actual tumors generally carry multiple mutations instead of just one or two. Numerous studies have pointed out the striking genetic differences between cell lines and tumor samples by comparing microarrays, copy number changes, mutations, and mRNA expression profiles. We offer CancerSeq AMS pre-screened tissue as mounted sections or curls.

Please inquire for other options, such as whole block or extracted nucleic acids. The list of targeted genes is also included in each product’s data sheet


Applications:

• Isolation of DNA with specific mutation profiles
• Validation of cancer marker mutation related drug candidates
• Companion diagnostic assay development
• Suitable for both IHC and in-situ hybridization assays
• Controls or verification for genotyping
• Cellular localization of tissue specific mRNA and protein expression

Advantages and Features:

• Deep sequencing by NGS with high coverage
• FFPE curls or slides available (inquire for blocks)
• Documentation of the tissue donor’s clinical histories is available
• Information regarding tumor type is available
• Complete NGS sequencing data available

Quality Data:

BioChain’s CancerSeq AMS pre-screened tissues come with detailed information regarding donor and cancer type, as well as NGS information such as chromosomal position, variant type (SNP or indel), alternate allele variations, quality score, depth of coverage, allele type, gene ID and more.